Kumar Harendra, Dhali Arkadeep, Biswas Jyotirmoy, Dhali Gopal Krishna
General Medicine, Dow University of Health Sciences, Karachi, PAK.
Internal Medicine, Sheffield Teaching Hospitals National Health Service (NHS) Foundation Trust, Sheffield, GBR.
Cureus. 2024 Aug 6;16(8):e66253. doi: 10.7759/cureus.66253. eCollection 2024 Aug.
A biologics license application (BLA) for sotatercept, a therapeutic agent targeting activin receptor signaling implicated in pulmonary arterial hypertension (PAH), has been granted priority review status by the FDA. This advancement underscores the critical need for novel pharmacological interventions for this rare and severe condition, potentially transforming the therapeutic landscape of PAH.
一种针对与肺动脉高压（PAH）相关的激活素受体信号传导的治疗药物索他西普的生物制品许可申请（BLA）已获得美国食品药品监督管理局（FDA）的优先审评资格。这一进展突显了针对这种罕见且严重疾病的新型药物干预措施的迫切需求，有望改变PAH的治疗格局。
